The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level

Leukemia Research

Volumn 30, Issue 5, 2006, Pages 575-582

  Yu, Wenjuan ^a   Rao, Qing ^a   Wang, Min ^a   Tian, Zheng ^a   Lin, Dong ^a   Liu, Xiangrong ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

17 Allylamide 17 demethoxygeldanamycin; Acute myeloid leukemia; Apoptosis; Differentiation; Heat shock protein 90; KIT

Indexed keywords

17 ALLYLAMIDE 17 DEMETHOXYGELDANAMYCIN; CELL PROTEIN; DNA FRAGMENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; SERINE; STEM CELL FACTOR; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GEL ELECTROPHORESIS; HEMATOPOIESIS; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; PRIORITY JOURNAL; RNA ISOLATION; WESTERN BLOTTING;

APOPTOSIS; ASPARAGINE; BENZOQUINONES; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HL-60 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOCYTIC, ACUTE; LYSINE; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33644849494     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.08.028     Document Type: Article

References (20)

1. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol Med 8 2002 S55 S61
2. T.W. Schulte, M.V. Blagosklonny, C. Ingui, and L. Neckers Disruption of the Raf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association J Biol Chem 270 1995 24585 24588
3. L. Whitesell, S.D. Shifrin, G. Schwab, and L.M. Neckers Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition Cancer Res 52 1992 1721 1728
4. L. Whitesell, E.G. Mimnaugh, B. De Costa, C.E. Myers, and L.M. Neckers Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc Natl Acad Sci USA 91 1994 8324 8328
5. T.W. Schulte, and L.M. Neckers The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother Pharmacol 42 1998 273 279
6. Y. Moriyama, T. Tsujimura, K. Hashimoto, M. Morimoto, H. Kitayama, and Matsuzawa Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase J Biol Chem 271 1996 3347 3350
7. H. Ikeda, Y. Kanakura, T. Tamaki, A. Kuriu, H. Kitayama, and J. Ishikawa Expression and functional role of the protooncogene c-kit in acute myeloblastic leukemia cells Blood 78 1991 2962 2968
8. A. Beghini, R. Cairoli, E. Morra, and L. Larizza In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation Blood Cells Mol Dis 24 1998 262 270
9. A. Beghini, P. Peterlongo, C.B. Ripamonti, L. Larizza, R. Cairoli, and E. Morra C-kit mutations in core binding factor leukemias Blood 95 2000 726 727
10. A. Beghini, C.B. Ripamonti, R. Cairoli, G. Cazzaniga, P. Colapietro, and F. Elice KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication Hematologica 89 2004 920 925
11. A. Beghini, P. Peterlongo, C.B. Ripamonti, L. Larizza, R. Cairoli, and E. Morra Amplification of a novel KIT activating mutation Asn822-Lys in the Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia Hematol J 3 2002 157 163
12. B.D. Smolich, H.A. Yuen, K.A. West, F.J. Giles, M. Albitar, and J.M. Cherrington The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts Blood 97 2001 1413 1421
13. G. Fumo, C. Akin, D.D. Metcalfe, and L. Neckers 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells Blood 103 2004 1078 1084
14. M. Ferrarini, S. Heltai, M.R. Zocchi, and C. Rugarli Unusual expression and localization of heat-shock proteins in human tumor cells Int J Cancer 51 1992 613 619
15. M. Higuchi, D. O'Brien, P. Kumaravelu, N. Lenny, E.J. Yeoh, and J.R. Downing Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukaemia Cancer Cell 1 2002 63 74
16. L.M. Kelly, and D.G. Gilliland Genetics of myeloid leukemias Ann Rev Genom Human Genet 3 2002 179 198
17. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, and J.M. Ford Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042
18. H. Joensuu, P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, and D. Tuveson Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 2001 1052 1056
19. Y. Minami, H. Kiyoi, Y. Yamamoto, K. Yamamoto, R. Ueda, and H. Saito Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by hsp90 inhibitors Leukemia 16 2002 1535 1540
20. J.T. Reilly Class III receptor tyrosine kinases: role in leukaemogenesis Br J Haematol 116 2002 744 757